Therefore, therapies targeting the MAPK/ERK pathway, such as BRAF and MEK inhibitors (e.g., vemurafenib, dabrafenib, trametinib, and selumetinib), can help control tumor growth and maintain dormancy. The gene discussed is BRAF; the disease is neoplasm.